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  DETERMINATION OF RALOXIFENE 
HYDROCHLORIDE IN HUMAN URINE 
BY LC-MS-MS 
A sensitive and selective liquid chromatographic-tandem mass spectrometric 
(LC-MS-MS) method was developed to determine raloxifene hydrochloride 
(RLX) in human urine. After a solid-phase extraction with SPE cartridge, the 
urine sample was analyzed on a C18 column (Symmetry 3.5µm; 50 mm×4.6 mm 
i.d) interfaced with a triple quadruple tandem mass spectrometer. A positive 
electrospray ionization was employed as the ionization source. The mobile 
phase consisted of ammonium acetate (pH 4.0)–acetonitrile (60:40, v/v).The 
method was linear over a concentration range of  20–1000 ng mL-1. The lower 
limit of quantitation was 20 ng mL-1. The intra-day and inter-day relative stan-
dard deviation across three validation runs over the entire concentration range 
was <10.5%. The accuracy determined at three concentrations (50, 500 and 
850 ng mL-1 RLX) was within ±0.84% in terms of relative errors. 
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Raloxifene hydrochloride (RLX) is a selective 
estrogen receptor modulator that belongs to the ben-
zothiophene class of compounds (Fig. 1) [1]. The che-
mical designation is methanone[6-hydroxy-2-(4-hyd-
roxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl) etho-
xy]phenyl] hydrochloride. RLX is used for the treat-
ment and prevention of osteoporosis in postmeno-
pausal women [2,3]. 
Only two HPLC methods [4,5] have been repor-
ted for the determination of RLX in body fluids. Tron-
telj et al. [6] have reported the determination of RLX in 
human plasma by LC-MS in the range of 0.088–60 
µg mL-1. 
The liquid chromatography-tandem mass spec-
trometry (LC-MS-MS), due to its higher sensitivity and 
selectivity, has been applied to the quantification of 
the drug in biological samples. The expected concen-
tration of RLX is primarily excreted in feces, and less 
than 0.2% is excreted unchanged in urine. Less than 
6% of the raloxifene dose is eliminated in urine as 
glucuronide conjugates [7]. 
The literature survey revealed that no method 
has been reported for the determination of RLX in hu-
man urine. 
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The present study was undertaken to develop a 
sensitive and rapid LC-MS-MS method for the deter-
mination of RLX in a urine sample using letrozole as 
an internal standard (Fig. 1). The sample preparation 
procedure was simple and a run time of each sample 
was 4.0 min. 
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Fig. 1. Structure of raloxifene hydrochloride (A) 
and internal standard (B). 
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EXPERIMENTAL 
Apparatus 
The LC-MS-MS analysis was performed with an 
API 2000 mass spectrometer (Applied Biosystems) 
coupled to an HPLC system comprising an Agilent 
1100 series  low pressure quaternary gradient pump 
with degasser, autosampler, and the column oven. 
Reagents and standards 
All chemicals used were of analytical reagent 
grade and HPLC grade acetonitrile (Merck Ltd, Mum-
bai) was used. Distilled water filtered through 0.22 µm 
filter (Millipore) was used to prepare the solutions. 
10 mM ammonium acetate (adjusted to pH 4.0 
with formic acid) and acetonitrile were used as a mo-
bile phase A and a mobile phase B, respectively. Ace-
tonitrile was used as the diluent for the urine extract. 
Pharmaceutical grade RLX, certified to be 99.8% 
pure was procured from Cipla India Ltd., Mumbai, In-
dia, and was used as received. A stock standard con-
taining a 100 µg mL-1 RLX solution was prepared by 
dissolving accurately weighed 1 mg of pure drug in a 
diluent and diluting it to 10 mL in a calibrated flask 
with the diluent. It was subsequently diluted to obtain 
a working concentration of RLX. 
Procedures 
LC-MS conditions 
The chromatographic separation was achieved 
at ambient temperature(25 °C) on the column (Sym-
metry, 3.5µm; 50 mm×4.6 mm i.d) using the mobile 
phase of 10mM ammonium acetate (pH 4.0, adjusted 
with formic acid) and acetonitrile in the ratio of 60:40 
(v/v) at a flow rate of 0.6 mL/min. The mobile phase 
was degassed before use. 
Quantization was performed by using the mul-
tiple reaction monitoring(MRM) of the transitions of 
m/z 474.6 → m/z 269.1 for raloxifene and m/z 284.2 → 
→ 257.5 m/z for letrozole (IS) with a scan time of 0.2 s 
per transition. The sensitivity and linearity range was 
observed for raloxifene and IS in these transition. So 
the same transition was used for quantization. 
Figure 2 shows the product ion spectra of [M+H]+ 
for raloxifene and letrozole. 
In order to optimize all the MS parameters, a 
standard solution (1 µg mL-1) of the analyte and IS 
was infused into the mass spectrometer. 
The analysis was performed in a positive mode 
(ESI-electro spray ionization) with a turbo ion spray 
interface under the conditions: ion source potential, 
5500 V; declustering potential, 70 V; focusing poten-
tial, 400 V, capillary temperature, 350 °C; entrance 
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Fig. 2. Full scan product ion spectra of raloxifene (a) and letrozole (b). 
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potential, 10 V with nitrogen as a nebuliser gas at 25 
Psi. The column eluent was introduced into the elec-
tro spray ionization chamber of the mass spectrome-
ter with a split ratio of 3:7. Mass fragmentation studies 
were performed by maintaining the normalized colli-
sion energy at 30 eV. 
Sample preparation 
The urine samples collected from healthy volun-
teers were spiked with known concentration of RLX 
and IS and the resulting sample was diluted 1:1 with 
water prior to loading on SPE cartridge (Oasis HLB, 
60 mg). The SPE cartridge was conditioned with 2mL 
of acetonitrile and equilibrated with 1 mL of water, 
and then diluted 1 mL urine was loaded on. The car-
tridge was then washed with 1 mL of 10% acetonitrile 
in water and then eluted with 1 mL of 100% acetoni-
trile. The sample was evaporated with nitrogen and 
reconstituted the residue with water:acetonitrile (1:1) 
to 500 µL. Then 20 µL of the above solution was in-
jected into LC-MS-MS for analysis. 
Preparation of standard and quality control samples 
The stock solution of RLX was prepared in ace-
tonitrile at the concentration of 10 µg mL-1. The stock 
solution of IS was prepared in acetonitrile at the con-
centration of 10 µg mL-1 and diluted to 500 ng mL-1 
with acetonitrile:water (1:1). The stock solutions were 
prepared in amber colored bottles and were stored in 
the refrigerator. 
A calibration curve was prepared by diluting the 
stock solution with acetonitrile:water (1:1) to get ap-
propriate concentrations. From this dilution, 20 µL of 
the appropriate standard solution was added to 1 mL 
of urine blank to get effective concentrations of 20, 
80, 100, 500, 850 and 1000 ng mL-1 for RLX. 
The quality control (QC) samples were separa-
tely prepared in the blank urine sample at the concen-
trations of 50, 500 and 850 ng/mL, respectively. The 
spiked urine samples (standards and quality controls) 
were then treated for SPE. 
RESULTS AND DISCUSSION 
Mass spectrometry 
The signal intensity obtained for RLX in the posi-
tive mode was much higher than that in the negative 
mode. Then, the possibility of using the electrospray 
ionization (ESI) or atmospheric pressure chemical ion-
ization (APCI) sources under the positive ion detec-
tion mode was evaluated during the early stage of the 
method development. ESI spectra revealed higher 
signals for the molecule compared to APCI source. A 
further assay development was therefore limited to 
ESI source. The Q1 full spectra of RLX and IS were 
dominated by protonated molecules [M+H]+ and no 
significant solvent adduct ions and fragments ions 
were observed. The tuning of the ESI source such as 
capillary temperature, a flow of sheath and auxiliary 
gas (N2) and the spray voltage on the transition of 
RLX and IS further improved the sensitivity. 
Chromatography 
Although in the aspect of chromatographic sepa-
ration the determination of the analyte was not inter-
fered with endogenous substances in the urine sam-
ple, yet the ionization of the analyte, especially of low 
concentration, was easily suppressed, which resulted 
in the linearity of narrow concentration range. In order 
to avoid the ion suppression induced by endogenous 
substances, the influence of the mobile phase that 
composed of different percentage of organic phase to 
the ion suppression was evaluated during the experi-
ment. It was found that when the mobile phase con-
sists of 10 mM ammonium acetate (pH 4.0)-aceto-
nitrile (60:40, v/v), the spiked sample demonstrated 
good linearity between 20 to 1000 ng mL-1 for RLX. 
Under the present chromatographic conditions, the 
run time of each sample was 4.0 min. The retention 
times were 0.91 min and 0.90 min for RLX and IS 
(Fig. 3), respectively. 
Method Validation 
Selectivity 
Selectivity was assessed by comparing the 
chromatograms of six different batches of blank urine 
samples with the corresponding spiked urine sample. 
Fig. 4 shows typical chromatograms of a blank for 
RLX and IS. There was no significant interference or 
ion suppression from endogenous substances 
observed at the retention times of the analytes. 
Linearity of calibration curves and 
lower limit of quantification 
Urine samples were quantified by using the ratio 
of the peak area of RLX to that of IS as the assay 
parameter. Peak area ratios were plotted against RLX 
concentrations and standard curves in the form of Y = 
= A + BX were calculated using weighted (1/x2) least 
squares linear regression. 
To evaluate linearity, urine calibration curves 
were prepared and assayed in duplicate on three se-
parate days. 
Visual inspection of the plotted duplicate calibra-
tion curves and correlation coefficients > 0.99 confir-
med that the calibration curves were linear over the 
concentration ranges of 20-1000 ng mL-1 for the ana-
lyte. 
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The lower limit of quantification was defined as the 
lowest concentration on the calibration curve for which 
the acceptable accuracy of ±15% and a precision be-
low 15% were obtained. The present LC-MS-MS me-
thod offered an LOQ of 20 ng mL-1 in 1 mL of the 
urine sample. 
Accuracy and precision 
The intra-day accuracy and precision were as-
sessed by determining QC samples in a set of six re-
plicates within one day. The accuracy was expressed 
by (mean observed concentration)/(spiked concen-
tration)×100 and the precision by relative standard 
deviation(RSD). 
Table 1 summarizes the precision and accuracy 
for the RLX evaluated by assaying the QC samples. 
The inter-day precision was established by perfor-
ming analyses over a period of five days on QC sam-
ples prepared afresh each day. 
Recovery study 
Absolute recoveries of RLX at three QC levels 
were determined by assaying the samples as des-
cribed above and comparing the peak areas of both 
RLX and IS with those obtained from a direct injection 
of the compounds dissolved in the blank urine. The re-
coveries of RLX, determined at three concentrations 
(50, 500 and 850 ng/mL) were 75.4±6.4%, 79.4±6.9% 
and 76.4±7.4% (n = 6) respectively. 
 
(a) 
 
(b) 
Fig. 3. Representative chromatogram of a) raloxifene (20 ng mL-1) and b) IS (500 ng mL-1). 
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Stability study 
It was found that the analyte in the urine sample 
was stable after three freeze-thaw cycles and at the 
24h post-preparative stability at room temperature.  
CONCLUSIONS 
A sensitive LC-MS-MS method for the quantifi-
cation of raloxifene in the urine sample was deve-
loped and validated. The method is rapid, sensitive 
and highly selective with a LOQ of 20 ng mL-1. The 
determination of one urine sample needs 4 min. 
These results indicate that it is suitable for the routine 
analysis of large batches of biological samples. 
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Fig. 4. Representative blank chromatogram for Raloxifene (a) and IS (b). 
Table 1. Accuracy and precision 
RLX taken, ng mL-1 RLX founda, ng mL-1 Intra-day RSDb, % Inter-day RSD, % REc, % 
50 49.8 8.3 10.5 0.40 
500 495.8 8.2 8.6 0.84 
850 846.6 7.7 7.8 0.40 
aMean value of seven determinations; brelative standard deviation; crelative error 
